This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

40/100

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Risk genes beyond APOE

Topic: Amyloid, tau and blood-test diagnosis

The complex etiology of Alzheimer's disease (AD) prompts scientists to develop multifunctional compounds to combat causes and symptoms of such neurodegeneration. To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor. The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Piazzi, L., Cavalli, A., Colizzi, F., Belluti, F., Bartolini, M., Mancini, F., et al. (2008). Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorganic & medicinal chemistry letters. https://doi.org/10.1016/j.bmcl.2007.09.100

Vancouver

Piazzi L, Cavalli A, Colizzi F, Belluti F, Bartolini M, Mancini F, et al. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorganic & medicinal chemistry letters. 2008. doi:10.1016/j.bmcl.2007.09.100. PMID: 17998161.

BibTeX

@article{piazzi2008-17998161,
  author  = {Piazzi, L. and Cavalli, A. and Colizzi, F. and Belluti, F. and Bartolini, M. and Mancini, F. and Recanatini, M. and Andrisano, V. and others},
  title   = {{Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds}},
  journal = {Bioorganic \& medicinal chemistry letters},
  year    = {2008},
  doi     = {10.1016/j.bmcl.2007.09.100},
  pmid    = {17998161},
  url     = {https://doi.org/10.1016/j.bmcl.2007.09.100}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor.
The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD.

Why it matters

Researchers designed and tested coumarin compounds that inhibit both acetylcholinesterase and the beta-site amyloid precursor protein cleavage enzyme (BACE1) in the laboratory. These are early chemical findings and no treatment, cure or prevention in people is reported.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Evidence strengthLow

How this study scored 40/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Bioorganic & medicinal chemistry letters)
Journal's citation record	2 / 4	Bioorganic & Medicinal Chemistry Letters: journal h-index 181 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2008 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 214 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	10.7 citations a year over 20 year(s) since 2008
Impact for its field and year	3 / 6	Cited 4.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	2 / 4	Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Angela Rampa: h-index 36 (OpenAlex, whole career)
Institution's track record	1 / 3	University of Bologna: institution h-index 989 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 17998161)
Free to read	0 / 2	Behind a paywall — scores zero
Total	40 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Risk genes beyond APOE

Also tagged “double-blind”

783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →